KR102083046B1 - 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 - Google Patents

레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 Download PDF

Info

Publication number
KR102083046B1
KR102083046B1 KR1020157000014A KR20157000014A KR102083046B1 KR 102083046 B1 KR102083046 B1 KR 102083046B1 KR 1020157000014 A KR1020157000014 A KR 1020157000014A KR 20157000014 A KR20157000014 A KR 20157000014A KR 102083046 B1 KR102083046 B1 KR 102083046B1
Authority
KR
South Korea
Prior art keywords
neutropenia
day
retinoid
pharmaceutical composition
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157000014A
Other languages
English (en)
Korean (ko)
Other versions
KR20150035983A (ko
Inventor
링타오 우
Original Assignee
칠드런＇스 하스피틀 로스 앤젤레스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런＇스 하스피틀 로스 앤젤레스 filed Critical 칠드런＇스 하스피틀 로스 앤젤레스
Publication of KR20150035983A publication Critical patent/KR20150035983A/ko
Application granted granted Critical
Publication of KR102083046B1 publication Critical patent/KR102083046B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157000014A 2012-06-07 2013-06-07 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 Expired - Fee Related KR102083046B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
KR20150035983A KR20150035983A (ko) 2015-04-07
KR102083046B1 true KR102083046B1 (ko) 2020-02-28

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000014A Expired - Fee Related KR102083046B1 (ko) 2012-06-07 2013-06-07 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법

Country Status (13)

Country Link
US (1) US11116738B2 (https=)
EP (1) EP2858636B1 (https=)
JP (1) JP6295249B2 (https=)
KR (1) KR102083046B1 (https=)
CN (1) CN104519879B (https=)
AU (1) AU2013270674B2 (https=)
BR (1) BR112014030279A2 (https=)
CA (1) CA2874850A1 (https=)
ES (1) ES2691493T3 (https=)
MX (1) MX365321B (https=)
NZ (1) NZ702415A (https=)
RU (1) RU2650962C2 (https=)
WO (1) WO2013185105A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
MX2016010699A (es) * 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
PL3277272T3 (pl) 2015-03-31 2022-01-24 Syros Pharmaceuticals, Inc. Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
EP3743722A4 (en) * 2018-01-26 2022-03-02 Agency for Science, Technology and Research NEUTROPHIL SUBTYPES
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506998A (ja) 1996-12-19 2001-05-29 アメリカン・サイアナミド・カンパニー 好中球減少症の治療または抑制方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
KR20060018851A (ko) 2003-05-16 2006-03-02 교와 핫꼬 고교 가부시끼가이샤 조직 파괴를 수반하는 질환의 예방 및/또는 치료제
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
ATE476981T1 (de) 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
TR201819157T4 (tr) * 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
EP2143428B1 (en) * 2007-03-30 2015-11-04 TMRC Co., Ltd. Tamibarotene capsule preparation
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
CN102612371B (zh) 2009-10-19 2014-03-19 莱拉营养食品有限公司 含有多聚乙酰的提取物，分馏物和混合物及它们的应用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA2826386C (en) 2011-02-08 2020-04-28 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
JP6242868B2 (ja) * 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506998A (ja) 1996-12-19 2001-05-29 アメリカン・サイアナミド・カンパニー 好中球減少症の治療または抑制方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Hematol., 26, 47-61(2009.)
Journal of Leukocyte Biology, 90, 235-247(2011.)

Also Published As

Publication number Publication date
ES2691493T3 (es) 2018-11-27
JP2015523346A (ja) 2015-08-13
AU2013270674A1 (en) 2014-12-18
JP6295249B2 (ja) 2018-03-14
AU2013270674B2 (en) 2017-12-07
WO2013185105A1 (en) 2013-12-12
HK1208630A1 (en) 2016-03-11
US11116738B2 (en) 2021-09-14
MX365321B (es) 2019-05-29
EP2858636A1 (en) 2015-04-15
US20150164836A1 (en) 2015-06-18
EP2858636A4 (en) 2016-06-01
CN104519879B (zh) 2018-10-02
BR112014030279A2 (pt) 2017-09-12
KR20150035983A (ko) 2015-04-07
CA2874850A1 (en) 2013-12-12
RU2014153988A (ru) 2016-07-27
MX2014014930A (es) 2015-07-06
CN104519879A (zh) 2015-04-15
NZ702415A (en) 2016-04-29
EP2858636B1 (en) 2018-09-05
RU2650962C2 (ru) 2018-04-18

Similar Documents

Publication Publication Date Title
KR102083046B1 (ko) 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
US20240366674A1 (en) Tumoricidal and antimicrobial compositions and methods
JP2022169781A (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
Drach et al. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid
JP6353073B2 (ja) 細胞回復のための組成物並びにその作製及び使用方法
US20160082071A1 (en) Methods of treating myeloid leukemia
US20260048083A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
EP3682889B1 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
US20160045573A1 (en) Nanoparticles with effects on endothelial function and membrane permeability
CN117980470A (zh) 治疗性nk细胞群
Zhang et al. Self-driven immune checkpoint blockade and spatiotemporal-sensitive immune response monitoring in acute myeloid leukemia using an all-in-one turn-on bionanoprobe
Ding et al. Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model
CN117159525A (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
US7629316B2 (en) Method for proliferating natural killer cells
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
SHARMA EXPLORING THE DRUG DELIVERY POTENTIAL OF MILK EXTRACELLULAR VESICLES FOR COMBATING INTRACELLULAR INFECTIONS IN MAMMARY EPITHELIAL CELLS
Cullen et al. Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade
KR20220091426A (ko) 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
CN114728068A (zh) Pd-1信号抑制剂的联合疗法
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
MX2007016597A (es) Componente purificado de algas azules-verdes y metodo de uso

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250225

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250225